-+ 0.00%
-+ 0.00%
-+ 0.00%

*Minerva Neurosciences: Confirmatory Phase 3 Trial of Roluperidone for Negative Symptoms of Schizophrenia Initiated, First Patient Screened >NERV

Dow Jones·05/05/2026 12:11:00

Please log in to view news